Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Certara CEO Honored in PharmaVOICE 100
August 05, 2015
Dr. Muniz Named as One of the 100 Most Inspiring Leaders in the Life Science Industry
PRINCETON, NJ – Aug. 05, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that its Chief Executive Officer, Edmundo Muniz, M.D., Ph.D., has been named one of the PharmaVOICE 100 “Commanders & Chiefs.” Dr. Muniz was recognized for his accomplishments as an expert clinician, medical researcher, and experienced businessman.
“Edmundo has built a committed, highly accomplished team at Certara through his extraordinary interpersonal skills and energy,” said Certara Chief Marketing Officer, Ellen Leinfuss. “One of the ways in which he motivates his team is by using the power of storytelling to demonstrate how each person’s efforts can collectively help to develop a novel drug which will bring a higher quality of life to patients.”
“I am very grateful for this recognition in the PharmaVOICE 100,” said Dr. Muniz. “Certara’s biosimulation technology has already helped reshape the drug development process, resulting in safer therapies brought to market at lower cost. Our mission is to continue to innovate in our products and services, working with our 1,500 clients and alongside the major regulatory agencies.”
Dr. Muniz joined Certara in June 2014 from Kirax Corporation, where he had served as President and CEO since 2005. Previously, he held several senior executive roles at Eli Lilly and Company, including Head of Worldwide Pharmacovigilance and Epidemiology, Cardiovascular Business Unit Leader, and Vice President of Oncology Clinical Development.
Dr. Muniz earned his M.D. from the Autonomous University of Santo Domingo in the Dominican Republic, and a Ph.D. in Population Planning and International Heath, and an M.S. in Population Planning from the University of Michigan, School of Public Health. He is also a graduate of the Epidemic Intelligence Service program and the Preventive Medicine Fellowship at the Centers for Disease Control and Prevention in Atlanta, Georgia.
About Certara
Certara is a global biosimulation technology-enabled drug development company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable superior drug development and regulatory decision-making through biosimulation, thus increasing R&D productivity and commercial value. For more information, visit www.certara.com.
Back to News